Russian Federal Drug Control Service Liquidation Commission

The Russian Federal Drug Control Service Liquidation Commission was responsible for overseeing the dissolution of the Federal Drug Control Service of Russia. Its primary function involved managing the transfer of the agency’s assets, personnel, and regulatory responsibilities to other state bodies. During its operation, the commission ensured that drug control policies and enforcement mechanisms continued uninterrupted despite the organizational change. The commission coordinated with law‑enforcement and health authorities to maintain oversight of narcotics trafficking and prescription drug regulation. These activities placed the commission within Russia’s broader public‑safety and counternarcotics framework.

Specific quantitative details about the commission’s staffing levels, budget, or geographic reach are not disclosed in the available source material. The organization’s headquarters was located in Russia, indicating a national scope of operation. As a federal liquidation body, its authority extended across the entire Russian Federation rather than being limited to a particular region. The lack of published size metrics means that any description of its scale must rely on its functional mandate rather than on numerical data. Consequently, the commission’s impact is best understood through its role in managing the discontinuation of a national drug‑control agency.

Distinguishing attributes of the commission include its specialized focus on the orderly winding down of a drug‑control regulator, a task that required legal, administrative, and logistical expertise. Unlike ongoing operational agencies, its mandate was time‑bound and centered on compliance with federal liquidation procedures. The commission’s work intersected with Russia’s counternarcotics strategy, ensuring that responsibilities previously held by the Federal Drug Control Service were not abandoned. Its notable competency lay in coordinating inter‑agency handover processes while preserving continuity of drug‑control measures. The 2016 DDoS attack against its website, carried out by the hacker Cryptolulz666 using a NetBIOS amplification technique, highlighted the commission’s exposure to cyber threats despite its transitional status.